Total Payments
$1.8M
2024 Payments
$183,915
Companies
25
Transactions
414
Payment Breakdown by Category
Research$1.8M (98.1%)
Other$17,875 (1.0%)
Consulting$8,800 (0.5%)
Food & Beverage$4,723 (0.3%)
Travel$2,589 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.8M | 152 | 98.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $17,875 | 9 | 1.0% |
| Consulting Fee | $8,800 | 16 | 0.5% |
| Food and Beverage | $4,723 | 232 | 0.3% |
| Travel and Lodging | $2,589 | 5 | 0.1% |
Payments by Type
Research
$1.8M
152 transactions
General
$33,987
262 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ModernaTX, Inc. | $1.6M | 114 | $0 (2024) |
| Moderna TX, Inc. | $88,254 | 2 | $0 (2021) |
| Allergan, Inc. | $79,320 | 29 | $0 (2022) |
| Genentech USA, Inc. | $25,278 | 33 | $0 (2022) |
| LEO Pharma AS | $14,950 | 2 | $0 (2019) |
| SANOFI PASTEUR INC. | $11,383 | 4 | $0 (2023) |
| Novavax Inc | $11,196 | 1 | $0 (2024) |
| PFIZER INC. | $4,303 | 81 | $0 (2024) |
| Shire North American Group Inc | $1,189 | 22 | $0 (2019) |
| Tris Pharma Inc | $738.17 | 44 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $183,915 | 45 | ModernaTX, Inc. ($172,294) |
| 2023 | $190,417 | 59 | ModernaTX, Inc. ($188,666) |
| 2022 | $917,214 | 75 | ModernaTX, Inc. ($904,866) |
| 2021 | $394,667 | 46 | ModernaTX, Inc. ($291,475) |
| 2020 | $72,913 | 56 | Allergan, Inc. ($51,515) |
| 2019 | $30,192 | 40 | LEO Pharma AS ($14,950) |
| 2018 | $1,534 | 58 | Shire North American Group Inc ($994.04) |
| 2017 | $4,839 | 35 | Allergan Inc. ($4,336) |
All Payment Transactions
414 individual payment records from CMS Open Payments — Page 1 of 17
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/03/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $18.48 | General |
| Category: UROLOGY | ||||||
| 11/21/2024 | Vertical Pharmaceuticals, LLC | Relexxii (Drug) | Food and Beverage | In-kind items and services | $16.48 | General |
| Category: Neurology - ADHD medication | ||||||
| 11/13/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $14.07 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 11/01/2024 | ModernaTX, Inc. | — | — | Cash or cash equivalent | $5,035.50 | Research |
| Study: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | ||||||
| 11/01/2024 | ModernaTX, Inc. | — | — | Cash or cash equivalent | $90.00 | Research |
| Study: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | ||||||
| 10/23/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $30.84 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 10/15/2024 | PFIZER INC. | PENBRAYA (Biological) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: VACCINES | ||||||
| 09/18/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $31.97 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 09/06/2024 | ModernaTX, Inc. | — | — | Cash or cash equivalent | $2,286.75 | Research |
| Study: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | ||||||
| 09/03/2024 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $65,917.87 | Research |
| Study: A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. • Category: Infections and Infectious Diseases | ||||||
| 09/03/2024 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $65.10 | Research |
| Study: A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. • Category: Infections and Infectious Diseases | ||||||
| 08/21/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $30.94 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 07/25/2024 | Novavax Inc | NOVAVAX COVID-19 VACCINE, ADJUVANTED (Biological) | — | Cash or cash equivalent | $11,196.20 | Research |
| Study: Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to younger than 12 Years • Category: Vaccine | ||||||
| 07/17/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $31.61 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 07/03/2024 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $64.00 | Research |
| Study: A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. • Category: Infections and Infectious Diseases | ||||||
| 06/26/2024 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $36,749.76 | Research |
| Study: A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. • Category: Infections and Infectious Diseases | ||||||
| 06/21/2024 | ModernaTX, Inc. | — | — | Cash or cash equivalent | $3,260.25 | Research |
| Study: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | ||||||
| 06/13/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $5.88 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 05/22/2024 | ModernaTX, Inc. | — | — | Cash or cash equivalent | $16,849.12 | Research |
| Study: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | ||||||
| 05/22/2024 | ModernaTX, Inc. | — | — | Cash or cash equivalent | $5,435.70 | Research |
| Study: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Healthy Younger Adults Aged 18 to 49 Years, Women of Child-Bearing Potential Aged 18 to 40 Years, Healthy Older Adults Aged 65 to 79 Years, and RSV-Seropositive Children Aged 12 to 59 Months | ||||||
| 05/22/2024 | ModernaTX, Inc. | — | — | Cash or cash equivalent | $5.60 | Research |
| Study: A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Healthy Younger Adults Aged 18 to 49 Years, Women of Child-Bearing Potential Aged 18 to 40 Years, Healthy Older Adults Aged 65 to 79 Years, and RSV-Seropositive Children Aged 12 to 59 Months | ||||||
| 05/15/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $28.84 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 05/15/2024 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $4.07 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 05/14/2024 | PFIZER INC. | PENBRAYA (Biological) | Food and Beverage | In-kind items and services | $29.23 | General |
| Category: VACCINES | ||||||
| 05/01/2024 | ModernaTX, Inc. | Moderna Covid-19 Vaccine (Biological) | — | Cash or cash equivalent | $2,091.52 | Research |
| Study: A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. • Category: Infections and Infectious Diseases | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | ModernaTX, Inc. | $1.2M | 68 |
| A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. | ModernaTX, Inc. | $123,874 | 12 |
| A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 12- to 30-year-old Healthy Adolescents and Adults | ModernaTX, Inc. | $99,854 | 13 |
| A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health | Moderna TX, Inc. | $88,254 | 2 |
| A Phase 1, Randomized, Observer-Blind, Placebo-Controlled,Dose Escalation Study to Evaluate the Safety, Reactogenicity,and Immunogenicity of mRNA-1345, an mRNA VaccineTargeting Respiratory Syncytial Virus (RSV), in HealthyYounger Adults Aged | ModernaTX, Inc. | $53,678 | 6 |
| Clinical Trial (LIN-MD-64: Ped FC Trial 6-17 Ph3) | Allergan, Inc. | $40,767 | 13 |
| Clinical Trial (LIN-MD-66: PED Longterm safety study) | Allergan, Inc. | $15,802 | 5 |
| PROTOPIC APPLES | LEO Pharma AS | $14,950 | 2 |
| Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants | ModernaTX, Inc. | $14,099 | 4 |
| An Open-Label, Phase 3 Study to Evaluate the Safety and Immunogenicity of the mRNA1273.214 Vaccine for SARS-CoV-2 Variants of Concern in Participants Aged 6 Months to < 6 Years | ModernaTX, Inc. | $13,520 | 4 |
| Study to Evaluate Safety and Immunogenicity of COVID-19 Vaccine in Children 6 Months to younger than 12 Years | Novavax Inc | $11,196 | 1 |
| A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 18- to 30-year-old Healthy Adults | ModernaTX, Inc. | $11,077 | 2 |
| A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), in Healthy Younger Adults Aged 18 to 49 Years, Women of Child-Bearing Potential Aged 18 to 40 Years, Healthy Older Adults Aged 65 to 79 Years, and RSV-Seropositive Children Aged 12 to 59 Months | ModernaTX, Inc. | $9,524 | 5 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED PARALLEL-GROUP, DOSE RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ELUXADOLINE IN PEDIATRIC PATIENTS AGED 12-17 WITH IRRITABLE BOWEL SYNDROME WITH DIARRHEA IBS-D | Allergan Inc. | $9,486 | 2 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, SAFETY AND EFFIACY STUDY OF A RANGE OF LINACLOTIDE DOSES ADMINISTERED ORALLY TO CHILDREN, AGES 6 TO 17 YEARS, WHO FULLFILL MODIFIED ROME III CRITERIA FOR CHILD ADOLESCENT FUNCTIONAL CONSTRIPATION FC | Allergan Inc. | $3,969 | 2 |
| Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Children Aged 2 to 9 Years | SANOFI PASTEUR INC. | $3,740 | 1 |
| Pediatric (12-17) Clinical Pharmacology/Efficacy/Safety Study | Allergan, Inc. | $3,621 | 3 |
| PNEUMOCOCCAL CONJ PNG CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,200 | 1 |
| Pediatric 12-17 Clinical PharmacologyEfficacySafety Study | Allergan Inc. | $2,997 | 1 |
| Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine | SANOFI PASTEUR INC. | $2,493 | 1 |
| Clinical Trial LIN-MD-64 Ped FC Trial 6-17 Ph3 | Allergan Inc. | $2,164 | 1 |
| Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adolescents and Adults | SANOFI PASTEUR INC. | $1,250 | 1 |
| A Phase 2, Randomized, Double-Blind Placebo-Controlled Parallel-group, Dose ranging study to Evaluate the Safety and Efficacy of Eluxadoline in Pediatric Patients Aged 12-17 with Irritable Bowel Syndrome with Diarrhea IBS-D | Allergan Inc. | $366.80 | 1 |
| APediatric (12-17) Clinical Pharmacology/Efficacy/Safety Study | Allergan, Inc. | $148.25 | 1 |
About Dr. Michael Simon, M.D
Dr. Michael Simon, M.D is a Pediatrics healthcare provider based in Nicholasville, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/03/2007. The National Provider Identifier (NPI) number assigned to this provider is 1992862205.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Simon, M.D has received a total of $1.8M in payments from pharmaceutical and medical device companies, with $183,915 received in 2024. These payments were reported across 414 transactions from 25 companies. The most common payment nature is "" ($1.8M).
Ad
Practice Information
- Specialty Pediatrics
- Location Nicholasville, KY
- Active Since 01/03/2007
- Last Updated 04/08/2013
- Taxonomy Code 208000000X
- Entity Type Individual
- NPI Number 1992862205
Products in Payments
- Moderna Covid-19 Vaccine (Biological) $1.5M
- Xofluza (Drug) $25,434
- PROTOPIC (Drug) $14,950
- VIBERZI (Drug) $12,849
- NOVAVAX COVID-19 VACCINE, ADJUVANTED (Biological) $11,196
- MENQUADFI (Biological) $6,233
- LINZESS (Drug) $6,133
- PREVNAR 13 (Biological) $3,315
- EUCRISA (Drug) $792.38
- Dyanavel XR (Drug) $738.17
- Azstarys (Drug) $632.14
- CIPRODEX (Drug) $329.61
- VYVANSE (Drug) $266.80
- PENBRAYA (Biological) $82.33
- PREVNAR - 13 (Biological) $61.21
- Otovel (Drug) $57.82
- Vyvanse (Drug) $48.84
- QBREXZA (Drug) $45.41
- QELBREE (Drug) $33.09
- Evekeo (Drug) $30.48
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatrics Doctors in Nicholasville
Dr. Jai Gilliam, M.d, M.D
Pediatrics — Payments: $7,802
Pediatrics $7,802
Sibel Gullo, M.d, M.D
Pediatrics — Payments: $7,695
Pediatrics $7,695
Apurva Subbaswamy, M.d, M.D
Pediatrics — Payments: $725.42
Pediatrics $725.42
Gary Weinberger, Md, MD
Pediatrics — Payments: $490.02
Pediatrics $490.02
William Revelette, Md, MD
Pediatrics — Payments: $140.82
Pediatrics $140.82
Mrs. Linda Lear, Md, MD
Pediatrics — Payments: $42.60
Pediatrics $42.60